For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Tafamidis and Attruby represents a true advancement . These innovative therapies preserve the transthyretin protein, preventing its damaging build-up and reducing the burden of the condition . Individuals are now experiencing positive